Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BioVie ( (BIVI) ) just unveiled an update.
BioVie Inc. has successfully closed its public offering, generating roughly $3 million by selling over 1.36 million shares, pre-funded warrants, and common warrants at $1.53 each. This strategic financial move is set to bolster the company’s working capital and support its corporate goals. Additionally, a significant adjustment to the exercise price of an existing Acuitas Warrant aligns with the new offering price, potentially influencing BioVie’s market dynamics and stakeholder interests. The company, known for developing drug therapies for chronic conditions and liver disease, reaffirms its commitment to innovation and growth in the biopharmaceutical sector.
Learn more about BIVI stock on TipRanks’ Stock Analysis page.
